Info

Adapted from Verstovsek et al.106

Adapted from Verstovsek et al.106

The 3-year overall, event-free, and relapse-free survival rates were 58, 48, and 56%, respectively. As expected, patients with ALCL had better outcomes than did other histologies (79 and 44%, respectively). Furthermore, these data appeared similar to those reported for stem cell transplant for relapsed high-grade B-cell lymphomas.91 Others have studied allogeneic HLA-matched sibling transplantation with combined marrow and CD34+-enriched peripheral blood stem cell transplantation after cytoreductive chemotherapy and TBI for refractory cutaneous T-cell lymphoma (CTCL), suggesting that this approach may be potentially beneficial for selected patients.92

0 0

Post a comment